Pharmacological comparison of the effect of ibogaine and 18-methoxycoronaridine on isolated smooth muscle from the rat and guinea-pig

British Journal of Pharmacology

Volumn 129, Issue 8, 2000, Pages 1561-1568

  Mundey, M K ^a   Blaylock, N A ^a   Mason, R ^a   Glick, S D ^b   Maisonneuve, I M ^b   Wilson, V G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

18 methoxycoronaridine; Guinea pig isolated ileum; Ibogaine; Purinergic transmission; Rat portal vein; Rat vas deferens; opioid receptors

Indexed keywords

18 METHOXYCORONARIDINE; ADENOSINE TRIPHOSPHATE; ALPHA 2 ADRENERGIC RECEPTOR; CORONARIDINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; IBOGAINE; MU OPIATE RECEPTOR; NALOXONE; PURINE RECEPTOR; UK 14303; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLADDER; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; ILEUM; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE; SMOOTH MUSCLE CONTRACTION; VAS DEFERENS;

EID: 0034000675     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703227     Document Type: Article

References (37)

1. AMBACHE, N. & ZAR, M.A. (1970). Non-cholinergic transmission by postganglionic motor neurones in the mammalian bladder. J. Physiol., 210, 761-785.
2. BAGAL, A.A., HOUGH, L.B., NALWALK, J.W. & GLICK, S.D. (1996). Modulation of morphine-induced antinociception by ibogaine and noribogaine. Brain Res., 741, 258-262.
3. BENWELL, M.E.M., HOLTAM, P.E., MORAN, R.J. & BALFOUR, D.J.K. (1996). Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br. J. Pharmacol., 117, 743-749.
4. CAPPENDIJK, S.L.T. & DZOLJIC, M.R. (1993). Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur. J. Pharmacol., 241, 261-265.
5. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
6. CODD, E.E. (1995). High affinity ibogaine binding to mu opioid agonist site. Life Sci., 57, 315-320.
7. DEECHER, D.C., TEITLER, M., SODERLUND, D.M., BORNMANN, W.G., KUEHNE, M.E. & GLICK, S.D. (1992). Mechanism of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res., 571, 242-247.
8. DELEAN, A., MUNSON, P.J. & RODBARD, D. (1978). Simultaneous analysis of families of sigmoidal curves: applications to bioassay, radioligand assay and physiological dose response curves. Am. J. Physiol., 235, E97-E102.
9. DOGGRELL, S.A. & BISHOP, B. (1996). Veratridine augments and BDF 9148 attenuates the spontaneous contractile force of the rat portal vein. J. Pharm. Pharmacol., 48, 820-824.
10. 2-purinoceptor antagonist in the mouse vas deferens. Br. J. Pharmacol., 93, 243-246.
11. FUJII, K. (1988). Evidence for adenosine triphosphate as an excitatory transmitter in guinea-pig, rabbit and pig urinary bladder. J. Physiol., 404, 39-52.
12. GLICK, S.D., KUEHNE, M.E., MAISONNEUVE, I.M., BANDARAGE, U.K. & MOLINARI, H.H. (1996a). 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self administration and on mesolimbic dopamine. Brain Res., 719, 29-35.
13. GLICK, S.D., KUEHNE, M.E., RAUCCI, J., WILSON, T.E., LARSON, D., KELLER, R.W. & CARLSON, J.N. (1994). Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res., 657, 14-22.
14. GLICK, S.D., MAISONNEUVE, I.M. & PEARL, S.M. (1997). Evidence for role of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res., 749, 340-343.
15. GLICK, S.D., PEARL, S.M., CIA, J. & MAISONNEUVE, I.M. (1996b). Ibogaine-like effects of noribogaine in rats. Brain Res., 713, 294-297.
16. GLICK, S.D., ROSSMAN, K., RAO, N.C., MAISONNEUVE, I.M. & CARLSON, J.N. (1991a). Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacol., 31, 497-500.
17. GLICK, D.D., ROSSMAN, K., STEINDORF, S., MAISONNEUVE, I.M. & CARLSON, J.N. (1991b). Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol., 195, 341-345.
18. HANDA, B.K., LAND, A.C., LORD, J.A., MORGAN, B.A., RANCE, M.J. & SMITH, C.F. (1981). Analogues of beta-LPH61-64 possessing selective agonist activity at μ-opiate receptors. Eur. J. Pharmacol., 70, 531-540.
19. HIDER, R.C., SMART, L. & SULEIMAN, M.S. (1981). The effect of harmaline and related β-carbolines on the acetylcholine-stimulated contractions of guinea-pig ileum. Eur. J. Pharmacol., 70, 429-436.
20. HONERJAGER, P. (1982). Cardioactive substances that prolong the open state of sodium channels. Rev. Physiol. Biochem. Pharmacol., 82, 1-74.
21. HOYLE, C.H.V., KNIGHT, G.E. & BURNSTOCK, G. (1990). Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli. Br. J. Pharmacol., 99, 617-621.
22. 2 purinoceptor: effect on non-adrenergic, non-cholinergic responses of the guinea-pig urinary bladder. Eur. J. Pharmacol., 86, 291-294.
23. KENNEDY, C. & HENDERSON, G. (1991). μ-Opioid receptor inhibition of calcium current: development of homologous tolerance in single SH-SY5Y cells after chronic exposure to morphine in vitro. Mol. Pharmacol., 40, 1000-1005.
24. LEFF, P. & DOUGALL, I.G. (1988). Estimation of opioid receptor agonist dissociation constants with β-chloronaltrexamine, an irreversible ligand which also displays agonism. Br. J. Pharmacol., 95, 234-240.
25. KOSTERLITZ, H.W. & HUGHES, J. (1978). Development of the concepts of opiate receptors and their ligands. Adv. Biochem. Psychopharmacol., 18, 31-44.
26. MAISONNEUVE, I.M., KELLER, R.W. & GLICK, S.D. (1991). Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur. J. Pharmacol., 199, 35-42.
27. 45Ca movements in rat isolated vascular smooth muscle. Eur. J. Pharmacol., 96, 251-259.
28. MILLER, L., SHAW, J.S. & WHITING, E.M. (1986). The contribution of intrinsic activity to the actions of opioids in vitro. Br. J. Pharmacol., 87, 595-601.
29. NESTLER, E.J. (1992). Molecular mechanism of drug addiction. J. Neurosci., 12, 1239-1250.
30. NIEBER, K., POELCHEN, W. & ILLES, P. (1997). Role of ATP in fast excitatory synaptic potentials in locus coeruleus neurons of the rat. Br. J. Pharmacol., 122, 423-430.
31. 35S]-GTPγS binding. NeuroReport, 9, 109-114.
32. PEARL, S.M., HERRICK-DAVIES, K., TEITLER, M. & GLICK, S.D. (1995). Radioligand binding study of noribogaine, a likely metabolite of ibogaine. Brain Res., 675, 342-344.
33. POPIK, P., LAYER, R.T., FOSSUM, L.H., BENVENISTE, M., GETER-DOUGLASS, WITKIN, J.M. & SKOLNICK, P. (1995b). NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J. Pharmacol. Exp. Ther., 275, 735-760.
34. POPIK, P., LAYER, R.T. & SKOLNICK, P. (1995a). 100 Years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev., 47, 235-253.
35. RABIN, R.A. & WINTER, J.C. (1996). Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors. Eur. J. Pharmacol., 316, 343-348.
36. SERSHEN, H., HASHIM, A. & LAJTHA, A. (1997). Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. Brain Res. Bull., 42, 161-168.
37. SWEETMAN, P.M., LANCASTER, J., SNOWMAN, A., COLLINS, J.L., PERSCHKE, S., BAUER, C. & FERKANY, J. (1995). Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology, 118, 369-376.